KPIs & Operating Metrics(New)
Breakdown Of AssetsCost Of Biosecurity Product RevenueCost Of Biosecurity Service RevenueCumulative ProgramsCumulative Programs AnnualCurrent Active ProgramsCurrent Active Programs AnnualDeferred RevenueGross Margin Biosecurity Product Revenue %Gross Margin Biosecurity Service Revenue %Gross Profit Biosecurity Product RevenueGross Profit Biosecurity Service RevenueIncome (Loss) Before Provisions For Income Tax By RegionNew ProgramsNew Programs AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Operating Income (Loss) By SegmentOperating Income (Loss) By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty And Equipment BreakdownRevenue By GeographyRevenue By Geography %Revenue By Industry Foundry RevenueRevenue By Industry Foundry Revenue %Revenue By Industry Foundry Revenue AnnualRevenue By Industry Foundry Revenue Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Total Active Customers AnnualTotal Active Customers Cell Engineering
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
AcquisitionsAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Return on Invested Capital Growth (3y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned
Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Ginkgo Bioworks Holdings (DNA) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $121.4 million as the latest value for Q4 2023.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|